Oncology Institute Stock Price

Key Takeaways New value-based care contracts and expanded partnerships are driving sustained growth and enhancing recurring revenue in a shifting oncology market. Operational efficiency initiatives, including automation and clinical trials outsourcing, are boosting margins and focusing resources on higher-growth opportunities.

Fourth Quarter 2024 Financial Highlights Consolidated revenue of $100 million, an increase of 16.9% compared to the prior year quarter Gross profit of $15 million, an increase of 1.8% compared to the prior year quarter Net loss of $13.2 million compared to net loss of $18.8 million for the prior year quarter Basic and diluted loss per share of $(0.14) and $(0.14), respectively, compared to $(0.21) and $(0.21) for the prior year quarter Adjusted EBITDA of $(7.8) million compared to $(6.3) million for the prior year quarter Cash, cash equivalents, and investments of $50 million as of December 31, 2024 (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.